- Strength in Numbers: How ASH Plans for the FutureJune 25, 2019 | July-August 2019, Volume 16, Issue 4
Dr. Silverstein stresses the important role different people, including staff, volunteers, and board and committee members, play in moving the Society forward and furthering its mission.
- Dealing With One Crisis Shouldn't Create AnotherMay 15, 2019
Drs. Clifford Hudis, Robert Carlson, and Roy Silverstein shed light on the importance of finding an approach to the opioid crisis that takes into account the needs of individuals who experience chronic pain as a result of hematologic conditions.
- Teachers and Preachers of Quality ImprovementApril 27, 2019 | May-June 2019, Volume 16, Issue 3
Dr. Silverstein discusses the Society's efforts to help hematologists become effective teachers and preachers of continuous quality improvement.
- In the Interest of TransparencyFebruary 21, 2019 | March-April 2019, Volume 16, Issue 2
Dr. Silverstein discusses the importance and challenges of managing conflicts of interest in medical science.
- Celebrating Our Strengths in 2019December 24, 2018 | January-February 2019, Volume 16, Issue 1
In his inaugural President's Column, Dr. Roy Silverstein reflects on the Society's accomplishments and sets priorities for the coming year.
- Is Anybody in Washington Listening?November 01, 2011 | November-December 2011, Volume 8, Issue 6
The fact is nearly all constituent communications are counted and responded to by Members of Congress and their staff. While it is true that individualized communications with some expression of personal sentiment or opinion are most likely to be influential, nearly all legislators do use constituent communications as a gauge of public opinion and integrate it into their decision-making.
- Revised PhRMA Code Goes into Effect: Sunshine or More of the Same?January 01, 2009 | January-February 2009, Volume 6, Issue 1
Recently, we have seen heightened attention by government officials and news media on financial relationships between physicians and manufacturers of pharmaceuticals and medical devices. A few notable cases of physicians and surgeons receiving six-figure "consulting" fees to promote drugs and devices often with little or no public disclosure have heightened interest.
- Another Piece in the Antiphospholipid Antibody Syndrome PuzzleNovember 01, 2007 | November-December 2007, Volume 4, Issue 6
Most patients with the pro-thrombotic condition known as antiphospholipid antibody (APLA) syndrome have circulating autoantibodies reactive with the phospholipid binding plasma protein β
-glycoprotein I (β
-GPI). Although β
-GPI circulates at very high concentrations (3μM) and has been studied for many years, its biologic function remains obscure. In this manuscript, a team from the Netherlands has uncovered a potential role for β
-GPI in regulating primary hemostasis.
- Fetal and Maternal Thrombophilia Genes Cooperate to Influence Pregnancy OutcomesSeptember 01, 2007 | September-October 2007, Volume 4, Issue 5
To study the impact of maternal thrombophilia on pregnancy outcomes, the authors carried out a series of elegant and complicated breeding experiments utilizing multiple mouse strains engineered with genetic defects in the protein C pathway.
- Bcl-2 Proteins Control Platelet Life Span In Vivo: A Potential Target for New Approaches to Treat ThrombocytopeniaJuly 01, 2007 | July-August 2007, Volume 4, Issue 4
Genome-wide mutagenesis (so-called “forward genetics”) has been used widely in non-vertebral model systems (including flies, worms, yeast, and bacteria) to discover pathways involved in numerous cellular processes. Similar approaches have been developed for mouse research, but are not widely used because of the time and costs related to mouse breeding.